Literature DB >> 33941261

Association of apolipoprotein B XbaI (rs693) polymorphism and gallstone disease risk based on a comprehensive analysis.

Haifeng Zhu1, Linhai Yu1, Linsong Feng2.   

Abstract

BACKGROUND: Our aim was to investigate the association between XbaI gene polymorphisms in the apolipoprotein B (APOB) gene and gallstone disease (GD) risk through a comparison of the allele and genotype distribution frequencies at this site using meta-analysis.
METHODS: A literature search was performed using PubMed and Wanfang through Jun 1, 2020. Odds ratios (ORs) and 95 % confidence intervals (CIs) were used to assess the strength of associations.
RESULTS: After a comprehensive search, 14 different articles that met the inclusion criteria were selected, with 1583 cases and 1794 controls. Individuals carrying the A-allele or AA genotype of the rs693 polymorphism were determined to possibly have an increased risk of GD. For example, there was a significant relationship between the rs693 polymorphism and increased GD risk in the whole group (OR: 1.40, 95 % CI: 1.05-1.87 in the allelic contrast model), the Asian population (OR: 1.58, 95 % CI: 1.48-2.84 in the heterozygote model), and the hospital-based source of the control (OR: 1.79, 95 % CI: 1.13-2.84 in the dominant model).
CONCLUSIONS: This study suggests that the APOB rs693 polymorphism is potentially associated with GD susceptibility, which might offer a detection marker for use in future large scale clinic research.

Entities:  

Keywords:  Apolipoprotein B; Gallstone disease; Meta‐analysis; Polymorphism; Risk

Year:  2021        PMID: 33941261     DOI: 10.1186/s41021-021-00189-z

Source DB:  PubMed          Journal:  Genes Environ        ISSN: 1880-7046


  1 in total

1.  IL-6 and IL-10 gene polymorphisms and cirrhosis of liver risk from a comprehensive analysis.

Authors:  Minghui Zheng; Weizhen Fang; Menglei Yu; Rui Ding; Hua Zeng; Yan Huang; Yuanyang Mi; Chaohui Duan
Journal:  BMC Endocr Disord       Date:  2021-12-09       Impact factor: 2.763

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.